Last $24.70 USD
Change Today +0.435 / 1.79%
Volume 622.0K
THOR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 08/26/14 All times are local (Market data is delayed by at least 15 minutes).

thoratec corp (THOR) Snapshot

Open
$24.33
Previous Close
$24.27
Day High
$24.87
Day Low
$24.33
52 Week High
10/31/13 - $43.58
52 Week Low
08/7/14 - $22.50
Market Cap
1.4B
Average Volume 10 Days
951.7K
EPS TTM
$1.31
Shares Outstanding
56.3M
EX-Date
--
P/E TM
18.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for THORATEC CORP (THOR)

thoratec corp (THOR) Related Businessweek News

No Related Businessweek News Found

thoratec corp (THOR) Details

Thoratec Corporation develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients. The company’s primary product lines include ventricular assist devices, such as HeartMate II, an implantable left ventricular assist device consisting of a rotary blood pump to provide intermediate and long-term mechanical circulatory support (MCS); and HeartMate XVE, an implantable and pulsatile left ventricular assist device for intermediate and longer-term MCS. Its ventricular assist devices also comprise CentriMag, an extracorporeal full-flow acute surgical support platform that offers support up to 30 days for cardiac and respiratory failure; and PediMag and PediVAS extracorporeal full-flow acute surgical support platforms designed to provide acute surgical support to pediatric patients. In addition, the company provides Paracorporeal Ventricular Assist Device, an external pulsatile ventricular assist device, which provides left, right, and biventricular MCS approved for bridge-to-transplantation (BTT), including home discharge and post-cardiotomy myocardial recovery; and Implantable Ventricular Assist Device, an implantable and pulsatile ventricular assist device designed to provide left, right, and biventricular MCS approved for BTT comprising home discharge and post-cardiotomy myocardial recovery. It sells its products through direct sales force and distributors in the United States and internationally. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.

951 Employees
Last Reported Date: 02/18/14
Founded in 1976

thoratec corp (THOR) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $570.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $302.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $338.3K
Compensation as of Fiscal Year 2013.

thoratec corp (THOR) Key Developments

Thoratec Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 28, 2014; Revises Earnings Guidance for the Year 2014

Thoratec Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 28, 2014. For the quarter, the company reported revenues of $118.1 million, a 10% decrease versus revenues of $130.5 million in the same period a year ago. Net income on a GAAP basis was $17.4 million, or $0.30 per diluted share, compared to GAAP net income of $23.2 million, or $0.40 per diluted share, in the same period last year. Non-GAAP net income, which is described later in this press release, was $24.4 million, or $0.43 per diluted share in the second quarter of 2014, compared to non-GAAP net income of $30.4 million, or $0.52 per diluted share, in the second quarter of 2013. Income from operations was $25.23 million against $33.04 million a year ago. Profit for the second quarter decreased from last year, reflecting a 10% decline in product sales. For the first six months of fiscal 2014, revenues were $243.8 million, a decrease of 10% over revenues of $248.2 million in the same period a year ago. Net income on a GAAP basis was $35.7 million, or $0.62 per diluted share, compared with GAAP net income of $41.4 million, or $0.71 per diluted share, in the same period a year ago. Non-GAAP net income was $48.1 million, or $0.84 per diluted share, compared with non-GAAP net income of $54.3 million, or $0.93 per diluted share, in the same period a year ago. Income from operations was $52.06 million against $56.44 million a year ago. The company is revising fiscal 2014 guidance for revenues to a range of $455 million to $470 million and net income per diluted share of $0.80 to $0.90 on a GAAP basis and $1.25 to $1.35 on a non-GAAP basis, down from the prior forecast for adjusted earnings in the range of $1.72 to $1.82 per share and revenues between $520 million and $535 million. Gross margin is expected to be approximately 69% on a GAAP basis and 70.5% on a non-GAAP basis. The company expects the effective tax rate to be approximately 31% on both a GAAP and non-GAAP basis.

Thoratec Corp., Q2 2014 Earnings Call, Aug 06, 2014

Thoratec Corp., Q2 2014 Earnings Call, Aug 06, 2014

Thoratec Corp. to Report Q2, 2014 Results on Aug 06, 2014

Thoratec Corp. announced that they will report Q2, 2014 results on Aug 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THOR:US $24.70 USD +0.435

THOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $56.96 USD +1.10
Merit Medical Systems Inc $12.62 USD +0.23
Orthofix International NV $33.98 USD -0.25
Tornier NV $21.32 USD +0.15
Wright Medical Group Inc $29.93 USD +0.23
View Industry Companies
 

Industry Analysis

THOR

Industry Average

Valuation THOR Industry Range
Price/Earnings 20.8x
Price/Sales 2.8x
Price/Book 2.0x
Price/Cash Flow 20.2x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THORATEC CORP, please visit www.thoratec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.